

canceled claims 24-27). New claims 34-37 correspond essentially to claims 24-37 in the originally filed application. Support for new claim 34 can be found in the specification as originally filed at, for example, page 6, lines 27-28, page 7, lines 2-3, page 10, lines 1-3, page 8 lines 14-16 and page 4, line 27 to page 5, line 1. Support for new claims 35-37 can be found in the specification as originally filed at, for example, page 5, lines 1-4. The Applicant notes that claims 34-37 have been amended to adopt the language of the allowed claims in related U.S. Patent No. 6,350,603.

## **II. The Amendments**

The Applicants would like to thank the Examiner for the phone conversation on Tuesday, July 1, 2003, during which the instant amendment and response were discussed. On Friday, June 27, 2003, the Applicants filed with the U.S. Patent Office a Preliminary Amendment and Response to Restriction Request wherein Applicants inadvertently elected and amended polypeptide claims 1 and 2 (Group I as identified by the Examiner). Which are currently being examined in related U.S. Patent Application Serial No. 10/034,015. Accordingly, the Applicants request entry of the instant amendment and response in place of the election made on June 27, 2003 and hereby elect claims 24-27 (Group IV as identified by the Examiner). As indicated above, claims 34-37 correspond to claims in elected Group IV. Upon entry of the present amendment, pending claims in the application will read as set out in Appendix A hereto.

The Applicant does not intend by this amendment or any other amendments to abandon the subject matter of any claim as originally filed. The Applicant reserves the right to pursue such subject matter in a duly filed continuing application.

The Applicant previously enclosed a check for \$930.00 and a petition for a three month extension of time with their response of June 27, 2003. Should any additional fees be deemed necessary in connection with the filing of this document, the Commissioner is hereby authorized to deduct any such fees from Marshall, Gerstein and Borun deposit account number 13-2855.

Respectfully submitted,  
MARSHALL, GERSTEIN & BORUN  
6300 Sears Tower  
233 South Wacker Drive  
Chicago, Illinois 60606-6357  
(312) 474-6300

By:



Eric M. Brusca  
Reg. No. 52,664

July 3, 2003

## **APPENDIX A**

### **Pending claims upon entry of present amendment**

34. (NEW) A method to identify a specific binding partner compound of a phosphodiesterase polypeptide encoded by a polynucleotide selected from the group consisting of:

- i) a polynucleotide comprising the sequence set forth in SEQ ID NO: 1;
  - ii) a polynucleotide encoding the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 23; and
  - iii) a polynucleotide that hybridizes under moderately stringent conditions to the non-coding strand of the polynucleotide of (i) or (ii); said moderately stringent conditions comprising a final wash at 65 degrees C in 2X SSC and 0.1%SDS,
- said method comprising the steps of:

- a) contacting the phosphodiesterase polypeptide with a compound under conditions which permit binding between the compound and the phosphodiesterase polypeptide;
- b) detecting binding of the compound to the phosphodiesterase polypeptide; and
- c) identifying the compound as a specific binding partner of the phosphodiesterase polypeptide.

35. (NEW) The method according to claim 34 wherein the specific binding partner modulates activity of the phosphodiesterase polypeptide.

36. (NEW) The method according to claim 35 wherein the compound inhibits activity of the phosphodiesterase polypeptide.

37. (NEW) The method according to claim 35 wherein the compound enhances activity of the phosphodiesterase polypeptide.